Brain histopathological study and prognosis in MOG antibody-associated demyelinating pseudotumor

Ann Clin Transl Neurol. 2019 Jan 8;6(2):392-396. doi: 10.1002/acn3.712. eCollection 2019 Feb.


Our objective was to examine the brain biopsies by histopathology and investigate the prognosis of patients with myelin oligodendrocyte glycoprotein antibody-associated demyelinating pseudotumor. The clinical, MRI, and histological features of two patients with myelin oligodendrocyte glycoprotein antibody-associated demyelinating pseudotumor were reviewed. Both patients were treated with steroid plus rituximab and followed up. The brain biopsies of both cases revealed T cells, macrophages, and complement-mediated demyelination, which was in accord with multiple sclerosis-like pathology. Moreover, both cases showed favorable response to steroid plus rituximab therapy. Our cases add a new variant to the myelin oligodendrocyte glycoprotein-encephalomyelitis spectrum, which favorably responds to immunotherapy.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Autoantibodies / adverse effects*
  • Demyelinating Diseases / chemically induced*
  • Demyelinating Diseases / diagnosis
  • Demyelinating Diseases / pathology
  • Encephalomyelitis / drug therapy
  • Encephalomyelitis / pathology
  • Humans
  • Immunologic Factors / metabolism
  • Male
  • Middle Aged
  • Multiple Sclerosis / drug therapy
  • Multiple Sclerosis / pathology
  • Myelin-Associated Glycoprotein / metabolism
  • Myelin-Oligodendrocyte Glycoprotein / metabolism*
  • Nervous System Malformations / drug therapy
  • Nervous System Malformations / pathology*
  • Oligodendroglia / drug effects
  • Oligodendroglia / metabolism


  • Autoantibodies
  • Immunologic Factors
  • Myelin-Associated Glycoprotein
  • Myelin-Oligodendrocyte Glycoprotein

Grants and funding

This work was funded by National Natural Science Foundation of China grants 81771300 and 81701188.